Researchers at Oregon State University have discovered, isolated, and purified a new antiproliferative compound, Coibamide A, which provides for a new and potent family of antiproliferative compounds. The peptidic molecular structure of Coibamide A presents a large number of possible combinations and permutations of component amino acid residues for structure activity relationship studies and/or drug development. Oregon State University is seeking a commercial licensee and research collaborator to further develop and bring this technology to market. If you are interested in learning more about this opportunity, please contact the licensing manager.
Features & Benefits
Background of Invention
Cancer is one of the leading causes of morbidity and mortality worldwide, and the number of cases is expected to rise to 22 million over the next 2 decades. Modified natural products continue to be an important source for new drugs that address unmet needs in the battle against cancer.
Issued U.S. Patent No. 8.034,780